(Xinhua photo)
WASHINGTON – A fourth Phase 3 clinical trial evaluating an investigational vaccine for the coronavirus disease 2019 (Covid-19) has begun enrolling adult volunteers, the US National Institutes of Health (NIH) announced on Wednesday.
The trial is designed to evaluate if the investigational Janssen Covid-19 vaccine JNJ-78436725 can prevent symptomatic Covid-19 after a single dose regimen, the NIH said in a release.
Up to 60,000 volunteers will be enrolled in the trial at up to nearly 215 clinical research sites in the United States and internationally.
The Janssen Pharmaceutical Companies of Johnson & Johnson developed the investigational vaccine and is leading the clinical trial as a regulatory sponsor.
The Janssen vaccine candidate is a recombinant vector vaccine that uses a human adenovirus to express the SARS-CoV-2 spike protein in cells.
The trial is designed primarily to determine if the investigational vaccine can prevent moderate to severe Covid-19 after a single dose.
It also aims to understand if the vaccine can prevent Covid-19 requiring medical intervention and if the vaccine can prevent milder cases of Covid-19 and asymptomatic SARS-CoV-2 infection, according to the NIH. (Xinhua)
